Two Cases of ALK Fusion Gene-positive Lung Adenocarcinoma Treated with Brigatinib After Alectinib-induced Interstitial Lung Disease

Abstract

━━ Background. Alectinib is an effective and well-tolerated agent for treating anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma. However, treatment with alectinib results in interstitial lung disease (ILD) as an adverse effect, thereby precluding therapy continuation. Several other ALK inhibitors have been studied in clinical trials